Covation Biomaterials announced that its first commercial plant for bio-based C4 products, including bioTHF and bioPTMEG, has reached mechanical completion. The plant is located in Qidong, Jiangsu Province, China, and the milestone marks a major step in reducing reliance on fossil fuels.
The facility was built with an investment of RMB 10 billion. It is planned in three phases. The first phase, now complete, has a capacity of 50,000 tons per year for both bioTHF and bioPTMEG.
Commercial production is expected to start in the second half of 2026. The plant aims for a total capacity of 500,000 tons annually once fully operational.
CovationBio also launched the Xatryx® brand for its new non-food, bioPTMEG products. This second-generation bio-based material serves as a drop-in replacement for fossil-based PTMEG. It helps customers reduce their carbon footprint while maintaining high performance in applications like spandex, polyurethanes, and thermoplastic elastomers.
Feifeng You, President of CovationBio, stated, “Xatryx® reflects our commitment to innovation and sustainability. Our process converts agricultural by-products directly into chemical feedstocks, supporting the defossilization of the materials industry.”
Xatryx® bioPTMEG offers several sustainability benefits. It significantly reduces greenhouse gas emissions compared to traditional PTMEG.
Made from renewable resources like corncobs, it does not compete with food supplies. It also provides a seamless switch for customers to adopt bio-based raw materials without changing their processes.
The post Covation Biomaterials completes first commercial plant for bioTHF and bioPTMEG appeared first on World Bio Market Insights.
